The Interaction of Amyloid-β with ApoE

The form of beta amyloid is a partial determinant of the interaction with Apolipoprotein E
  • Donald B. Carter
Part of the Subcellular Biochemistry book series (SCBI, volume 38)


Brain plaque deposition in the form of amyloid-beta (Aβ) peptide is a pathological hallmark of Alzheimer’s disease (AD). Apolipoprotein E (ApoE) is thought to be involved in plaque formation. Individuals afflicted with AD carrying the ApoE4 isoform have shown a greater number of Aβ plaques when compared to ApoE3 carriers, and inheritance of an ApoE4 allele increases the risk of AD when compared to ApoE2 and ApoE3 carriers. The role of ApoE in the pathogenesis of AD is not well understood but a hypothesis gaining widespread support is that ApoE is involved in deposition or clearance of Aβ by direct protein-to-protein interaction. We have established that various human Aβ conformations apparent during spontaneous aggregation confer differing degrees of binding to the three ApoE isoforms. When associated with lipid, ApoE4 bound preferentially to an intermediate aggregated form of Aβ and had higher avidity than did ApoE2 or ApoE3.

Key words

Apolipoprotein E (ApoE) amyloid-beta (Aβ) protofibrils cerebral spinal fluid (CSF) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aieshkov, S., Abraham, C.R., and Zannis, V.I., 1997, Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer’s disease. Biochemistry 36: 10571–10580.CrossRefGoogle Scholar
  2. Aleshkov, S.B., Li, X., Lavrentiadou, S.N., and Zannis, V.I., 1999, Contribution of cysteine 158, the glycosylation site threonine 194, the amino-and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40). Biochemistry 38: 8918–8925.PubMedCrossRefGoogle Scholar
  3. Arai, Y., Mizuguchi, M., Ikeda, K., and Takashima, 1995, Developmental changes of apolipoprotein E immunoreactivity in Down syndrome brains. Brain Res. Dev. 87: 228–232.CrossRefGoogle Scholar
  4. Bales, K.R., Verina, T., Dodel, R.C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone E.M., Little, S.P., Cummins, D.J., Piccardo, P., Ghetti, B., and Paul, S.M., 1997, Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nature Genet. 17: 263–264.PubMedCrossRefGoogle Scholar
  5. Bales, K.R., Verina, T., Cummins, D.J., Du, Y., Dodel, R.C., Saura, J., Fishman, C.E., DeLong, C.A., Piccardo, P., Petegnief, V., Ghetti, B., and Paul, S.M., 1999, Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 96: 15233–15238.PubMedCrossRefGoogle Scholar
  6. Bentley, N.M., Ladu, M.J., Rajan, C., Getz, G.S., and Reardon, C.A., 2002, Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(l–40): the role of salt bridges. Biochem. J. 366: 273–279.PubMedGoogle Scholar
  7. Carter, D.B., Dunn, E., McKinley, D.D., Stratman, N.C., Boyle, T.P., Kuiper, S.L., Oostveen, J.A., Weaver, R.J., Boller, J.A., and Gurney, M.E., 2001, Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain. Ann. Neurol. 50: 468–475.PubMedCrossRefGoogle Scholar
  8. Castano, E.M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R.A., Soto, C., and Frangione, B., 1992, Fibrillogenesis in Alzheimer’s disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 306: 599–604.Google Scholar
  9. Chan, W., Fornwald, J., Brawner, M., and Wetzel, R., 1996, Native complex formation between apolipoprotein E isoforms and the Alzheimer’s disease peptide A beta. Biochemistry 35: 7123–7130.PubMedCrossRefGoogle Scholar
  10. Cho, H.S., Hyman, B.T., Greenberg, S.M., and Rebeck, G, W., 2001, Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J. Neuropathol. Exp. Neurol. 60: 342–349.PubMedGoogle Scholar
  11. Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A.Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, L, and Selkoe, D.J., 1992, Mutation of the beta-amyloid precursor protein in familial Alzheimer’s disease increases beta-protein production. Nature. 360: 672–674.PubMedCrossRefGoogle Scholar
  12. Corbo, R.M., and Scacchi, R., 1999, Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? Ann. Hum. Genet. 63: 301–310.PubMedCrossRefGoogle Scholar
  13. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., and Pericak-Vance, M.A., 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261: 921–923.PubMedCrossRefGoogle Scholar
  14. Corder, E.H., Saunders, A.M., Risch, N.J., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C. Jr, Rimmler, J.B., Locke, P.A., Conneally, P.M., Schmader, K.E., and Roses, A.D., 1994, Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet. 7: 180–184.PubMedCrossRefGoogle Scholar
  15. Dong, L.M., Wilson, C., Wardell, M.R., Simmons, T., Mahley, R.W., Weisgraber, K.H., and Agard, D.A., 1994, Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269: 22358–22365.PubMedGoogle Scholar
  16. Dong, L.M., and Weisgraber, K.H., 1996, Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem. 271: 19053–19057.PubMedCrossRefGoogle Scholar
  17. Fagan, A.M., Holtzman, D.M., Munson, G., Mathur, T., Schneider, D., Chang, L.K., Getz, G.S., Reardon, C.A., Lukens, J., Shah, J.A., and LaDu, M, J., 1999, Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J. Biol. Chem. 1999 274: 30001–30007.PubMedCrossRefGoogle Scholar
  18. Fagan, A.M., Watson, M., Parsadanian, M., Bales, K.R., Paul, S.M., and Holtzman, D.M., 2002, Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer’s disease. Neumbiol. Dis. 9: 305–318.CrossRefGoogle Scholar
  19. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., and Gillespie F, 1995, Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523–527.PubMedCrossRefGoogle Scholar
  20. Gearing, M., Mori, H., and Mirra, S.S., 1996, Aϑ-peptide length and apolipoprotein E genotype in Alzheimer’s disease. Ann. Neurol. 39: 395–399.PubMedCrossRefGoogle Scholar
  21. Golabek, A.A., Soto, C., Vogel, T., and Wisniewski, T., 1996, The interaction between apolipoprotein E and Alzheimer’s amyloid beta-peptide is dependent on beta-peptide conformation. J. Biol. Chem. 271: 10602–10606.PubMedCrossRefGoogle Scholar
  22. Golabek, A.A., Kida, E., Walus, M., Perez, C., Wisniewski, T., and Soto, C., 2000, Sodium dodecyl sulfate-resistant complexes of Alzheimer’s amyloid beta-peptide with the N-terminal, receptor binding domain of apolipoprotein E. Biophys. J. 79: 1008–1015.PubMedGoogle Scholar
  23. Gravina, S.A., Ho, L., Eckman, C.B., Long, K.E., Otvos, L., Jr, Younkin, L.H., Suzuki, N., and Younkin, S.G., 1995, Amyloid beta protein (A beta) in Alzheimer’s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 270: 7013–7016.PubMedCrossRefGoogle Scholar
  24. Holtzman, D.M., Bales, K.R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A.M., Chang, L.K., Sun, Y., Paul, S.M., 1999, Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer’s disease. J. Clin. Invest. 103:R15–R21.PubMedGoogle Scholar
  25. Holtzman, D..M., Bales, K.R., Tenkova, T., Fagan, A.M., Parsadanian, M., Sartorius, L.J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., and Paul, S.M., 2000a, Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 97: 2892–2897.PubMedCrossRefGoogle Scholar
  26. Holtzman, D.M., Fagan, A.M., Mackey, B., Tenkova, T., Sartorius, L., Paul, S.M., Bales, K., Ashe, K.H., Irizarry, M.C., and Hyman, B, T., 2000b, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model. Ann. Neurol. 47:739–747.PubMedCrossRefGoogle Scholar
  27. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G., 1996, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99–102.PubMedCrossRefGoogle Scholar
  28. Ishii, K., Tamaoka, A., Mizusawa, H., Shoji, S., Ohtake, T., Fraser, P.E., Takahashi, H., Tsuji, S., Gearing, M., Mizutani, T., Yamada, S., Kato, M., St George-Hyslop, P.H., Mirra, S.S., and Mori, H., 1997, Abeta 1-40 but not Abeta 1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer’s disease. Brain Res. 748:250–252.PubMedCrossRefGoogle Scholar
  29. LaDu, M.J., Falduto, M.T., Manelli, A.M., Reardon, C.A., Getz, G.S., and Frail, D.E., 1994, Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 269: 23403–23406.PubMedGoogle Scholar
  30. LaDu, M.J., Pederson, T.M., Frail, D.E., Reardon, C.A., Getz, G.S., and Falduto, M.T., 1995, Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J. Biol. Chem. 270: 9039–9042.PubMedCrossRefGoogle Scholar
  31. LaDu, M.J., Gilligan, S.M., Lukens, J.R., Cabana, V.G., Reardon, C.A., Van Eldik, L.J., and Holtzman, D.M., 1998, Nascent astrocyte particles differ from lipoproteins in CSF. J. Neurochem. 70: 2070–2081.PubMedCrossRefGoogle Scholar
  32. Lemere, C.A., Blusztajn, J.K., Yamaguchi, H., Wisniewski, T., Saido, T.C., and Selkoe, D.J., 1996, Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3: 16–32.PubMedCrossRefGoogle Scholar
  33. LeVine, H., 2000, 125I-labeled ApoE binds competitively to beta(l–40) fibrils with pathological chaperone proteins. Amyloid 7: 83–89.PubMedCrossRefGoogle Scholar
  34. Linton, M.F., Gish, R., Hubl, S.T., Butler, E., Esquivel, C., Bry, W.I., Boyles, J.K., Wardell, M.R., and Young, S.G., 1991, Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88: 270–281.PubMedGoogle Scholar
  35. Ma, J., Yee, A., Brewer, H.B. Jr, Das, S., and Potter, H., 1994, Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372: 92–94.PubMedCrossRefGoogle Scholar
  36. Mann, D.M., Iwatsubo, T., Pickering-Brown, S.M., Owen, F., Saido, T.C., and Perry, R.H., 1997, Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer’s disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci. Lett. 221: 81–84.PubMedCrossRefGoogle Scholar
  37. McNamara, M.J., Gomez-Isla, T., and Hyman, B.T., 1998, Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch. Nenrol. 55: 1001–1004.CrossRefGoogle Scholar
  38. Meyer, M.R., Tschanz, J.T., Norton, M.C., Welsh-Bohmer, K.A., Steffens, D.C., Wyse, B.W., and Breitner, J.C., 1998, APOE genotype predicts when—not whether—one is predisposed to develop Alzheimer disease. Nature Genet. 19: 321–322.PubMedCrossRefGoogle Scholar
  39. Morishima-Kawashima, M., Oshima, N., Ogata, H., Yamaguchi, H., Yoshimura, M., Sugihara, S., and Ihara, Y., 2000, Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am. J. Pathol. 157: 2093–2099.PubMedGoogle Scholar
  40. Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., and Ikeda, K., 1991, Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541: 163–166.PubMedCrossRefGoogle Scholar
  41. Namba, Y., Tsuchiya, H., and Ikeda, K., 1992, Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer’s disease. Neurosci. Lett. 134: 264–266.PubMedCrossRefGoogle Scholar
  42. Naslund, J., Thyberg, J., Tjernberg, L.O., Wernstedt, C., Karlstrom, A.R., Bogdanovic, N., Gandy, S.E., Lannfelt, L., Terenius, L., and Nordstedt, C., 1995, Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer’s disease brain. Neuron 15: 219–228.PubMedCrossRefGoogle Scholar
  43. Pillot, T., Goethals, M., Najib, J., Labeur, C., Lins, L., Chambaz, J., Brasseur, R., Vandekerckhove, J., and Rosseneu, M., 1999, Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer’s disease. J. Neurochem. 72: 230–237.PubMedCrossRefGoogle Scholar
  44. Pitas, R.E., Boyles, J.K., Lee, S.H., Foss, D., and Mahley, R.W., 1987a, Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917: 148–161.PubMedGoogle Scholar
  45. Pitas, R.E., Boyles, J.K., Lee, S.H, Hui, D., and Weisgraber, K, H., 1987b, Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 262: 14352–14360.PubMedGoogle Scholar
  46. Rebeck, G.W., Reiter, J.S., Strickland, D.K., and Hyman, B.T., 1993, Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 11: 575–580.PubMedCrossRefGoogle Scholar
  47. Sanan, D.A., Weisgraber, K.H., Russell, S.J., Mahley, R.W., Huang, D., Saunders, A., Schmechel, D., Wisniewski, T., Frangione, B., Roses, A.D., and Strittmatter, W.J., 1994), Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94: 860–869.PubMedCrossRefGoogle Scholar
  48. Saunders, A.M., Strittmatter, W.J., Schmechel, D., St. George-Hyslop, P., et al., 1993), Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43: 1467–1472.PubMedGoogle Scholar
  49. Schmechel, D.E., Saunders, A.M., Strittmatter, W.J., Crain, B.J., Pericak-Vance, S.H., et al., 1993, Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci. U.S.A. 90: 9649–9653.PubMedCrossRefGoogle Scholar
  50. Selkoe, D.J., 2002, Alzheimer’s disease is a synaptic failure. Science 298: 789–791.PubMedCrossRefGoogle Scholar
  51. Shuvaev, V.V., and Siest, G., 1996, Interaction between human amphipathic apolipoproteins and amyloid beta-peptide: surface plasmon resonance studies. FEBS Lett. 383: 9–12.PubMedCrossRefGoogle Scholar
  52. Soto, C., Golabek, A., Wisniewski, T., and Castano, E.M., 1996, Alzheimer’s beta-amyloid peptide is conformationally modified by apolipoprotein E in vitro. Neuroreport 7: 721–725.PubMedGoogle Scholar
  53. Stratman, N.C., Castle, C., Taylor, B.M., Epps, D.E., MeIchior, G.W., and Carter, D.B., 2003, Isoform specific interactions of human apolipoprotein E to and intermediate conformation of human alzheimer amyloid-beta peptide. Neurobiol. Dis. in review.Google Scholar
  54. Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., and Roses, A.D., 1993a, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90: 1977–1981.PubMedCrossRefGoogle Scholar
  55. Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y., Dong, L.M., Salvesen, G.S., Pericak-Vance, M., Schmechel, D., Saunders, A.M., Goldgaber, D., and Roses, A.D., 1993b, Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90:8098–8102.PubMedCrossRefGoogle Scholar
  56. Strittmatter, W.J., and Roses, A.D., 1996, Apolipoprotein E and Alzheimer’s disease. Ann. Rev. Neurosci. 19: 53–77.PubMedCrossRefGoogle Scholar
  57. Suzuki, N., Cheung, T.T., Cai, X.D., Odaka, A., Otvos, L. Jr, Eckman, C., Golde, T.E., and Younkin, S.G., 1994, An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264: 1336–1340.PubMedCrossRefGoogle Scholar
  58. Taylor, B.M., Sarver, R.W., Fici, G., Poorman, R.A., Lutzke, B.S., Molinari, A., Kawabe, T., Kappenman, K., Buhl, A.E., and Epps, D.E., 2003, Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta l–40: a kinetic model. J. Protein Chem. 22: 31–40.PubMedCrossRefGoogle Scholar
  59. Tokuda, T., Calero, M., Matsubara, E., Vidal, R., Kumar, A., Permanne, B., Zlokovic, B., Smith, J.D., Ladu, M.J., Rostagno, A., Frangione, B., and Ghiso, J., 2000, Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides. Biochem. J. 348: 359–365.PubMedCrossRefGoogle Scholar
  60. Weisgraber, K.H., 1994, Apolipoprotein E: Structure-Function Relationships. In: Advances in Protein Chemistry 45, pp. 249–295.PubMedCrossRefGoogle Scholar
  61. Wisniewski, T., and Frangione, B., 1992, Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135: 235–238.PubMedCrossRefGoogle Scholar
  62. Wisniewski, T., Castano, E.M., Golabek, A., Vogel, T., and Frangione, B., 1994, Acceleration of Alzheimer’s fibril formation by apolipoprotein E in vitro. Am. J. Pathol 145: 1030–1035.PubMedGoogle Scholar
  63. Wisniewski, T., Lalowski, M., Golabek, A., Vogel, T., and Frangione, B., 1995, Is Alzheimer’s disease an apolipoprotein E amyloidosis? Lancet 345: 956–958.PubMedCrossRefGoogle Scholar
  64. Zhou, Z., Smith J.D., Greengard, P., and Gandy, S., 1996, Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Mol. Med. 2: 175–180.PubMedCrossRefGoogle Scholar
  65. Yang, D.S., Smith, J.D., Zhou, Z., Gandy, S.E., Martins, R.N., 1997, Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J. Neurochem. 68: 721–725PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Donald B. Carter
    • 1
  1. 1.CNS TherapeuticsPfizer CorporationKalamazooUSA

Personalised recommendations